Epigenomics Moves Methylation-Based Prostate Cancer Prognostic to Affy Platform | GenomeWeb
NEW YORK (GenomeWeb News) —  Epigenomics yesterday said it has transferred its PCR-based prostate cancer prognostic test to Affymetrix’ GeneChip platform.
The company said a concordance study showed a 98-percent agreement between the two platforms.  
Epigenomics said the development of its test is “on track” and expecting to begin clinical trials in the US and Europe some time in 2007.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.